BR0116380A - Método e composições que empregam formulaçoes de óleos de lecitina e fármacos antiinflamatórios não-esteróides (nsaids) para proteger o trato gastrointestinal e proporcionar maior atividade terapêutica - Google Patents

Método e composições que empregam formulaçoes de óleos de lecitina e fármacos antiinflamatórios não-esteróides (nsaids) para proteger o trato gastrointestinal e proporcionar maior atividade terapêutica

Info

Publication number
BR0116380A
BR0116380A BR0116380-9A BR0116380A BR0116380A BR 0116380 A BR0116380 A BR 0116380A BR 0116380 A BR0116380 A BR 0116380A BR 0116380 A BR0116380 A BR 0116380A
Authority
BR
Brazil
Prior art keywords
nsaids
therapeutic activity
protect
gastrointestinal tract
provide greater
Prior art date
Application number
BR0116380-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Lenard Lichtenberger
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of BR0116380A publication Critical patent/BR0116380A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR0116380-9A 2000-12-19 2001-12-19 Método e composições que empregam formulaçoes de óleos de lecitina e fármacos antiinflamatórios não-esteróides (nsaids) para proteger o trato gastrointestinal e proporcionar maior atividade terapêutica BR0116380A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25671100P 2000-12-19 2000-12-19
PCT/US2001/051605 WO2002085414A2 (en) 2000-12-19 2001-12-19 Nsaid formulations comprising lecithin oils for protecting the gastrointestinal tract and providing enhanced therapeutic activity

Publications (1)

Publication Number Publication Date
BR0116380A true BR0116380A (pt) 2005-04-05

Family

ID=22973287

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0116380-9A BR0116380A (pt) 2000-12-19 2001-12-19 Método e composições que empregam formulaçoes de óleos de lecitina e fármacos antiinflamatórios não-esteróides (nsaids) para proteger o trato gastrointestinal e proporcionar maior atividade terapêutica

Country Status (17)

Country Link
EP (1) EP1343529B1 (enExample)
JP (2) JP4958381B2 (enExample)
KR (1) KR100884493B1 (enExample)
CN (2) CN102258457B (enExample)
AT (1) ATE414542T1 (enExample)
AU (1) AU2001297778B2 (enExample)
BR (1) BR0116380A (enExample)
CA (1) CA2431606C (enExample)
CY (1) CY1110474T1 (enExample)
DE (1) DE60136647D1 (enExample)
DK (1) DK1343529T3 (enExample)
ES (1) ES2317873T3 (enExample)
IL (2) IL156361A0 (enExample)
MX (1) MXPA03005550A (enExample)
PT (1) PT1343529E (enExample)
SI (1) SI1343529T1 (enExample)
WO (1) WO2002085414A2 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1653975A4 (en) * 2003-07-31 2006-10-25 Univ Texas COMPOSITIONS AND METHODS FOR TREATING, PREVENTING AND / OR PREVENTING CANCER, THE USE OF CANCER OR THE SYMPTOMS OF CANCER
US20050176809A1 (en) * 2004-02-05 2005-08-11 Rodlen Laboratories, Inc. Method and compositions for treatment of painful disorders
WO2005084683A1 (fr) * 2004-03-03 2005-09-15 MARTINS, José, Araujo Composition a base de lecithine vegetale, ex. de soja, vitamines du complexe b et d'acide acetylsalicylique, et son utilisation pour la fabrication d'un medicament pour le traitement des maladies neuro-degeneratives
KR20070063587A (ko) * 2004-10-12 2007-06-19 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 정제된 인지질-비스테로이드성 소염 약물 연합 조성물 및이의 제조방법 및 사용방법
GB0517673D0 (en) * 2005-08-31 2005-10-05 Astrazeneca Ab Formulation
CA2626579A1 (en) * 2005-10-25 2007-05-03 Abbott Laboratories Formulation comprising a drug of low water solubility and method of use thereof
CA2657769C (en) 2006-07-19 2014-11-18 The Board Of Regents Of The University Of Texas System Preparations of phospholipids and pharmaceuticals containing 5-amino salicylic acid for the treatment of inflammatory bowel disease
WO2009039505A1 (en) * 2007-09-20 2009-03-26 Rutgers, The State University Of New Jersey Compositions and methods for treating cardiovascular conditions
GB2477590A (en) * 2010-02-05 2011-08-10 Biocopea Ltd A non-steroidal anti-inflammatory drug (NSAID) formulation comprising a lipid carrier
EP2629779B1 (en) * 2010-10-22 2017-06-21 Dr. Reddy's Laboratories SA. Use of storage stable viscous phospholipid depot to treat wounds
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US8895537B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating cardiovascular diseases
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9737500B2 (en) 2010-10-29 2017-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
WO2012104655A2 (en) * 2011-02-04 2012-08-09 Biocopea Limited Compostions and methods for treating chronic inflammation and inflammatory diseases
WO2013022410A2 (en) 2011-08-08 2013-02-14 Mahmut Bilgic Production method for effervescent formulations comprising dexketoprofen
WO2013049749A2 (en) 2011-09-29 2013-04-04 Plx Pharma Inc. pH DEPENDENT CARRIERS FOR TARGETED RELEASE OF PHARMACEUTICALS ALONG THE GASTROINTESTINAL TRACT, COMPOSITIONS THEREFROM, AND MAKING AND USING SAME
US10286093B2 (en) * 2013-05-23 2019-05-14 Neurosn, Inc. Method of diagnosing and treating Alzheimer's disease
US9446056B2 (en) * 2014-02-11 2016-09-20 Dr. Reddy's Laboratories Ltd. Parenteral compositions of celecoxib
CN103908454B (zh) * 2014-04-17 2016-08-24 兆科药业（广州）有限公司 一种药物组合物及其制备方法和应用
WO2016094617A1 (en) * 2014-12-11 2016-06-16 Phosphorex, Inc. Aqueous topical drug formulation with controlled release and increased stability
CN104739843A (zh) * 2015-04-15 2015-07-01 郭志标 一种用于治疗口腔溃疡的药物组合物
AU2019231699B2 (en) * 2018-03-07 2023-03-09 Andrew Xian Chen Aqueous formulations for insoluble drugs
CN108542909B (zh) * 2018-03-30 2020-07-07 浙江海昶生物医药技术有限公司 一种阿司匹林磷脂固化组合物、其制备方法及药物制剂
JP7229012B2 (ja) * 2018-12-25 2023-02-27 小林製薬株式会社 内服用医薬組成物
KR20220158031A (ko) 2020-03-26 2022-11-29 피엘엑스 옵코 인코포레이티드 pH 의존성 재구성이 가능한 제약 담체 및 그의 제조 및 사용 방법
CN120643509B (zh) * 2025-08-18 2025-12-05 杭州市滨江区浙医二院经血管植入器械研究院 血管内长效留存的油相药物溶液及液体灌注球囊传递方式

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60208910A (ja) * 1984-03-31 1985-10-21 Green Cross Corp:The 水難溶性薬物・リン脂質複合体の製造方法
US5154930A (en) 1987-03-05 1992-10-13 The Liposome Company, Inc. Pharmacological agent-lipid solution preparation
US5091188A (en) 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
JPH07503952A (ja) * 1992-02-12 1995-04-27 ジヤンセン・シラグ・ソチエタ・ペル・アチオニ リポソームピロキシカム組成物
EP1214940B1 (en) * 1995-01-27 2009-03-11 Board of Regents, The University of Texas System Methods of enhancing the therapeutic activity of NSAIDs and compositions of zwitterionic phospholipids useful therein
US5955451A (en) * 1995-05-12 1999-09-21 The University Of Texas System Board Of Regents Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein

Also Published As

Publication number Publication date
HK1161107A1 (en) 2012-08-24
KR20030072565A (ko) 2003-09-15
EP1343529A2 (en) 2003-09-17
AU2001297778C1 (en) 2002-11-05
CA2431606A1 (en) 2002-10-31
CN102258457A (zh) 2011-11-30
IL156361A0 (en) 2004-01-04
MXPA03005550A (es) 2004-05-14
JP2005506303A (ja) 2005-03-03
JP4958381B2 (ja) 2012-06-20
IL156361A (en) 2011-04-28
PT1343529E (pt) 2009-02-27
DE60136647D1 (de) 2009-01-02
WO2002085414A2 (en) 2002-10-31
KR100884493B1 (ko) 2009-02-18
ES2317873T3 (es) 2009-05-01
CY1110474T1 (el) 2015-04-29
WO2002085414A3 (en) 2003-05-08
AU2001297778B2 (en) 2007-05-31
CA2431606C (en) 2011-07-19
EP1343529B1 (en) 2008-11-19
CN1543358A (zh) 2004-11-03
JP2010031044A (ja) 2010-02-12
CN102258457B (zh) 2015-07-01
DK1343529T3 (da) 2009-03-16
ATE414542T1 (de) 2008-12-15
SI1343529T1 (sl) 2009-04-30

Similar Documents

Publication Publication Date Title
IL156361A0 (en) Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providing enhanced therapeutic activity
KR101769010B1 (ko) Trpv1 선택적 작용제를 포함하는 통증 완화 조성물, 및 이의 제조방법 및 용도
KR102073258B1 (ko) 통증 완화용 국소 조성물, 제조방법 및 용도
PT1282446E (pt) Composição farmacêutica e/ou cosmética contendo um organossiloxano e um fodfolípido
AU2023222925B2 (en) Strontium based compositions and formulations for pain, pruritus, and inflammation
BRPI9811989B1 (pt) uso do ácido 9-cis retinóico para a fabricação de um medicamento
JP2000515526A (ja) Ｍｔｐ阻害剤と他のコレステロール低下薬を組合せて使用する、血清脂質レベルの降下方法
AU2310200A (en) Pharmaceutical compositions
ES2178430T3 (es) Utilizacion de composiciones farmaceuticas gelificables en parodontologia.
KR20110017451A (ko) 소염 진통 외용제
MA27093A1 (fr) Derives de sulfonamides, leur preparation et leur application comme medicaments.
BR0109012A (pt) Composição farmacêutica, forma de dosagem unitária, solução oral, método para o tratamento da dor, e, método para o tratamento de inflamações
BRPI0513673B8 (pt) método para produzir um medicamento para aumentar a eficácia e o transporte dos compostos biologicamente ativos enteralmente administrados, e composição farmacêutica
CA2264979A1 (fr) Composes bicycliques-aromatiques et leur utilisation en medecine humaine ou veterinaire ainsi qu'en cosmetologie
US12121536B2 (en) Strontium based compositions and formulations for pain, pruritus, and inflammation
CA2334843A1 (fr) Composes diarylselenures et leur utilisation en medecine humaine ou veterinaire ainsi qu'en cosmetologie
JP2012193159A (ja) 鼻用スプレー
CA2291650A1 (fr) Nouveaux composes heteroethynylenes et compositions pharmaceutiques et cosmetiques les contenant
JP2000229884A (ja) 皮膚外用剤
ATE91890T1 (de) Herstellung eines arzneimittels gegen arthritis und rheumatismus.
JP3187806B2 (ja) ニトロイミダゾール系化合物を含むアトピー性皮膚炎治療用の外用剤
CA2958169C (en) Strontium-based compositions and formulations for pain, itching, and inflammation
JP5050851B2 (ja) 疼痛治療剤
US20050042241A1 (en) Dr. Bob's Arthritis Cream
JP3568881B2 (ja) 皮膚疾患治療用外用剤

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: A61K 47/24, A61K 47/44, A61K 9/06, A61K 9/08, A61K 9/10, A61K 9/107, A61K 31/167, A61K 31/192, A61K 31/616, A61P 29/00, A61P 9/00, A61P 7/02, A61P 1/02, A61P 1/04, A61P 25/28, A61P 27/02, A61P 35/00, A61P 43/00

Ipc: A61K 47/00 (2011.01)

B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]